<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875559</url>
  </required_header>
  <id_info>
    <org_study_id>REG-028-2021</org_study_id>
    <nct_id>NCT04875559</nct_id>
  </id_info>
  <brief_title>Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study</brief_title>
  <official_title>Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is one of the most common types of cancer among women worldwide. (1)&#xD;
      Breast-conserving surgery or mastectomy is indicated for the majority of patients with this&#xD;
      type of cancer. (2) Postoperative pain is frequent in this population, with almost 50 %&#xD;
      experiencing acute pain and 25-60 % subsequently live with chronic pain. (3-5) Today no&#xD;
      golden standard for postoperative pain management regarding breast cancer surgeries exists,&#xD;
      and there is definitely room for improvement. Especially considering the large population of&#xD;
      women with breast cancer and consequences of acute and chronic pain, such as prolonged&#xD;
      recovery and affected quality of life. (6,7) With the present study, we aim to optimise&#xD;
      postoperative pain treatment and investigate the effect of a standardised multimodal&#xD;
      postoperative analgesic regimen based on previous recommendations. (4,8,9)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">April 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Postoperative day 1 to 7.</time_frame>
    <description>Postoperative pain scored on the 11-point numeric rating scale, NRS, (score 0 = no pain, 10 = worst pain imaginable). Average pain, worst pain and pain during arm abduction to an angle of 90 degrees out from the body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at the day-case post anaesthesia care unit (dcPACU)</measure>
    <time_frame>From arrival to the dcPACU until discharged from the dcPACU, up to 5 hours</time_frame>
    <description>Pain at dcPACU arrival and worst pain during dcPACU stay, scored on the 11-point numeric rating scale, NRS, (score 0 = no pain, 10 = worst pain imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postanaesthesia recovery time</measure>
    <time_frame>From arrival to the dcPACU until discharged from the dcPACU, up to 5 hours</time_frame>
    <description>Length of stay at day-case post anaesthesia care unit (dcPACU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>Postoperative day 1 to 7.</time_frame>
    <description>Nausea on average and at worst, measured on a four-point Likert scale (0 = none, 1 = slight, 2 = moderate, 3 = severe). Vomiting (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily use of analgesics</measure>
    <time_frame>Postoperative day 1 to 7.</time_frame>
    <description>Type of drug and dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of pain</measure>
    <time_frame>Day of surgery (preoperative) and postoperative day 1 to 7.</time_frame>
    <description>Patient's perceived location of pain preoperatively and postoperatively (questionnaire options: breast, side of chest, axilla, arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sleep</measure>
    <time_frame>Postoperative day 1 to 7.</time_frame>
    <description>Patient's perceived quality of sleep (questionnaire options: good, difficulty of falling asleep, frequent awakenings, no sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well-being</measure>
    <time_frame>Postoperative day 1 to 7.</time_frame>
    <description>Patient's perceived feelings of sadness (yes/no), restlessness (yes/no), or fatigue (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery, QoR-15D</measure>
    <time_frame>Postoperative day 1 and 7.</time_frame>
    <description>The QoR-15D is a validated questionnaire (danish version) resulting in a score of 1-150.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Breast cancer surgery patients.</arm_group_label>
    <description>Patients scheduled for day-case unilateral breast conserving surgery or mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy. No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardised multimodal pain treatment regimen</intervention_name>
    <description>Preoperatively:&#xD;
Paracetamol 1000 mg p.o.&#xD;
Celecoxib 400 mg p.o.&#xD;
Dexamethasone 12 mg p.o.&#xD;
Perioperatively:&#xD;
Ondansetron 4 mg IV&#xD;
Bupivacaine 2.5 mg/mL, 20 mL LIA&#xD;
Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)&#xD;
Postoperatively:&#xD;
Paracetamol 1000 mg p.o. every 6h PRN&#xD;
Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN&#xD;
Oxycodone 5 mg IV or 10 mg p.o. PRN&#xD;
Ondansetron 4 mg IV or p.o. PRN</description>
    <arm_group_label>Breast cancer surgery patients.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients scheduled for breast conserving surgery or mastectomy with or without ALND or&#xD;
        SLNB at Zealand University Hospital, Roskilde, will be invited to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for day-case unilateral breast conserving surgery or mastectomy +/-&#xD;
             ALND or SLNB.&#xD;
&#xD;
          -  Age ≥ 18 years of age.&#xD;
&#xD;
          -  Patients who received written and oral information, and have signed the informed&#xD;
             consent form on participation in the study.&#xD;
&#xD;
          -  Patients living in the Region of Zealand.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able to speak, read, or understand Danish.&#xD;
&#xD;
          -  Inability to cooperate and to consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Sofie N Therkelsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Sofie N Therkelsen, MD</last_name>
    <phone>004523342732</phone>
    <email>ather@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ole Mathiesen, MD, ph.d.</last_name>
    <email>omat@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zealand University Hospital, Department of Anaesthesiology</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Sofie N Therkelsen, MD</last_name>
      <phone>+4523342732</phone>
      <email>ather@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.</citation>
    <PMID>33538338</PMID>
  </reference>
  <reference>
    <citation>Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018 Jul;13(3):339-354. doi: 10.1016/j.cpet.2018.02.006. Review.</citation>
    <PMID>30100074</PMID>
  </reference>
  <reference>
    <citation>Habib AS, Kertai MD, Cooter M, Greenup RA, Hwang S. Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study. Reg Anesth Pain Med. 2019 Feb;44(2):192-199. doi: 10.1136/rapm-2018-000040. Epub 2019 Jan 5.</citation>
    <PMID>30700614</PMID>
  </reference>
  <reference>
    <citation>Lepot A, Elia N, Tramèr MR, Rehberg B. Preventing pain after breast surgery: A systematic review with meta-analyses and trial-sequential analyses. Eur J Pain. 2021 Jan;25(1):5-22. doi: 10.1002/ejp.1648. Epub 2020 Oct 4. Review.</citation>
    <PMID>32816362</PMID>
  </reference>
  <reference>
    <citation>Gärtner R, Kroman N, Callesen T, Kehlet H. Multimodal prevention of pain, nausea and vomiting after breast cancer surgery. Minerva Anestesiol. 2010 Oct;76(10):805-13.</citation>
    <PMID>20935616</PMID>
  </reference>
  <reference>
    <citation>Gong Y, Tan Q, Qin Q, Wei C. Prevalence of postmastectomy pain syndrome and associated risk factors: A large single-institution cohort study. Medicine (Baltimore). 2020 May;99(20):e19834. doi: 10.1097/MD.0000000000019834.</citation>
    <PMID>32443289</PMID>
  </reference>
  <reference>
    <citation>Sagen A, Kåresen R, Sandvik L, Risberg MA. Changes in arm morbidities and health-related quality of life after breast cancer surgery - a five-year follow-up study. Acta Oncol. 2009;48(8):1111-8. doi: 10.3109/02841860903061691.</citation>
    <PMID>19863218</PMID>
  </reference>
  <reference>
    <citation>Jacobs A, Lemoine A, Joshi GP, Van de Velde M, Bonnet F; PROSPECT Working Group collaborators#. PROSPECT guideline for oncological breast surgery: a systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia. 2020 May;75(5):664-673. doi: 10.1111/anae.14964. Epub 2020 Jan 26.</citation>
    <PMID>31984479</PMID>
  </reference>
  <reference>
    <citation>Steinthorsdottir KJ, Awada HN, Abildstrøm H, Kroman N, Kehlet H, Aasvang EK. Dexamethasone Dose and Early Postoperative Recovery after Mastectomy: A Double-blind, Randomized Trial. Anesthesiology. 2020 Apr;132(4):678-691. doi: 10.1097/ALN.0000000000003112.</citation>
    <PMID>31977520</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multimodal pain management</keyword>
  <keyword>Opioid-sparing pain management</keyword>
  <keyword>Quality of recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

